Adjuvant Chemotherapy for ER+/PR+/HER2- Breast Cancer

Core Treatment Principles

The National Comprehensive Cancer Network recommends that all patients with ER+/PR+/HER2- invasive breast cancer should receive adjuvant endocrine therapy regardless of age, lymph node status, or whether chemotherapy is administered 1, 2
Adjuvant endocrine therapy is mandatory for all ER+/PR+/HER2- breast cancer patients, while the decision to add chemotherapy depends primarily on genomic testing (21-gene recurrence score) combined with nodal status, tumor size, grade, and patient age 3, 4

For node-negative disease, the 21-gene recurrence score (Oncotype DX) should be used to guide chemotherapy decisions, with a recurrence score of 0-10 indicating no benefit from adding chemotherapy to endocrine therapy 3, 4
For patients with a recurrence score of 11-25, age ≤50 years and RS 16-25, chemotherapy should be added before endocrine therapy, while for age >50 years or RS 11-15, endocrine therapy alone is sufficient 3, 4
For node-positive disease (1-3 positive nodes), the RxPONDER trial results guide treatment, with a recurrence score ≤25 indicating a small absolute benefit from chemotherapy, and a recurrence score ≥31 indicating a clear benefit from adjuvant chemotherapy 3, 4

When both chemotherapy and endocrine therapy are indicated, chemotherapy must be given first, followed by sequential endocrine therapy, as tamoxifen decreases the annual odds of recurrence by 41% and death by 31% when given after chemotherapy 1, 2

For postmenopausal women, aromatase inhibitors (anastrozole, letrozole, or exemestane) are preferred over tamoxifen for 5-10 years, reducing annual odds of recurrence by approximately 5% in absolute terms compared to tamoxifen 5, 6
For premenopausal women, tamoxifen 20 mg daily for 5-10 years is the standard approach, while high-risk premenopausal patients may be considered for ovarian function suppression plus aromatase inhibitor 1, 2, 5, 6

The standard duration of endocrine therapy is 5 years for both tamoxifen and aromatase inhibitors, while extended therapy to 10 years total may be recommended for node-positive disease to reduce late recurrence risk 5, 6

Preferred regimens include anthracycline-based followed by taxanes (AC→paclitaxel or docetaxel) and docetaxel-cyclophosphamide, as taxanes provide particular benefit in hormone receptor-positive disease by overcoming relative chemoresistance 6

For ER-low-positive tumors (1-10% staining), individualized risk-benefit assessment is mandatory for both endocrine therapy and chemotherapy, as these patients may derive limited benefit from endocrine therapy alone and should be considered for chemotherapy more liberally 2, 7, 6
Menopausal status assessment cannot be determined while receiving ovarian function suppression, and monitoring estradiol and FSH/LH levels is recommended in certain situations 1, 2, 5
The 21-gene assay (Oncotype DX) is the only multigene assay clinically validated for predicting chemotherapy benefit, not just prognosis, and should be used to guide chemotherapy decisions in this population 3, 4

For patients with HR-positive, node-negative breast cancer and Oncotype DX recurrence score greater than 25, the National Comprehensive Cancer Network recommends treatment with chemotherapy followed by hormone therapy, not chemotherapy alone 8, 9, 10

For patients with RS 26-30, chemotherapy followed by endocrine therapy is recommended, with the American College of Surgeons and the National Comprehensive Cancer Network suggesting that the absolute benefit is more modest compared to RS ≥31 8, 9, 10
Consider patient age: younger patients (≤50 years) derive greater benefit from chemotherapy in this RS range, according to the National Comprehensive Cancer Network 9, 10

Endocrine therapy alone (without chemotherapy) would be inappropriate for RS >25, as these patients have demonstrated benefit from chemotherapy, as stated by the National Comprehensive Cancer Network 8, 9, 10

The TAILORx trial showed that patients ≤50 years with RS 16-25 had lower rates of distant recurrence with chemotherapy addition, as reported by the National Comprehensive Cancer Network 8, 9, 10
For node-negative disease with RS >25, the evidence for chemotherapy benefit is clear, according to the National Comprehensive Cancer Network 8, 9, 10
For node-positive disease with RS ≤25, the RxPONDER trial showed benefit only in premenopausal women, as stated by the National Comprehensive Cancer Network 11, 8, 9